163 related articles for article (PubMed ID: 38709249)
21. Rilonacept and Other Interleukin-1 Inhibitors in the Treatment of Recurrent Pericarditis.
Goel A; Bandyopadhyay D; Malik AH; Gupta R; Frishman WH; Aronow WS
Cardiol Rev; 2023 Jul-Aug 01; 31(4):225-229. PubMed ID: 36398320
[TBL] [Abstract][Full Text] [Related]
22. Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept.
Lin D; Klein A; Cella D; Beutler A; Fang F; Magestro M; Cremer P; LeWinter MM; Luis SA; Abbate A; Ertel A; Litcher-Kelly L; Klooster B; Paolini JF
BMC Cardiovasc Disord; 2021 Apr; 21(1):201. PubMed ID: 33882846
[TBL] [Abstract][Full Text] [Related]
23. Autoimmune and Autoinflammatory Pericarditis: Definitions and New Treatments.
Bizzi E; Trotta L; Pancrazi M; Nivuori M; Giosia V; Matteucci L; Montori D; Brucato A
Curr Cardiol Rep; 2021 Jul; 23(9):128. PubMed ID: 34319478
[TBL] [Abstract][Full Text] [Related]
24. Pediatric Recurrent Pericarditis: Appropriateness of the Standard of Care and Response to IL-1 Blockade.
Caorsi R; Insalaco A; Bovis F; Martini G; Cattalini M; Chinali M; Rimini A; Longo C; Federici S; Celani C; Filocamo G; Consolini R; Maggio MC; Fadanelli G; Licciardi F; Romano M; Teruzzi BL; Taddio A; Miniaci A; La Torre F; De Fanti A; Cavalli G; Bigucci B; Gallizzi R; Chinello M; Imazio M; Brucato A; Cimaz R; De Benedetti F; Gattorno M
J Pediatr; 2023 May; 256():18-26.e8. PubMed ID: 36470465
[TBL] [Abstract][Full Text] [Related]
25. What is rilonacept's role in treating recurrent pericarditis?
Schwier NC
JAAPA; 2022 Nov; 35(11):18-19. PubMed ID: 36282574
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of colchicine in addition to anakinra in patients with recurrent pericarditis.
Collini V; Andreis A; De Biasio M; De Martino M; Isola M; Croatto N; Lepre V; Cantarini L; Merlo M; Sinagra G; Abbate A; Lazaros G; Brucato A; Klein AL; Imazio M
Open Heart; 2024 Mar; 11(1):. PubMed ID: 38490715
[TBL] [Abstract][Full Text] [Related]
27. Hydroxychloroquine for colchicine-resistant glucocorticoid-dependent idiopathic recurrent pericarditis: A pilot observational prospective study.
Lazaros G; Antonopoulos AS; Antonatou K; Skendros P; Ritis K; Hadziyannis E; Lazarou E; Leontsinis I; Simantiris S; Vlachopoulos C; Tousoulis D; Vassilopoulos D
Int J Cardiol; 2020 Jul; 311():77-82. PubMed ID: 32312616
[TBL] [Abstract][Full Text] [Related]
28. Interventions for reducing inflammation in familial Mediterranean fever.
Wu B; Xu T; Li Y; Yin X
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010893. PubMed ID: 30338514
[TBL] [Abstract][Full Text] [Related]
29. Anti-interleukin-1 agents for pericarditis: a primer for cardiologists.
Imazio M; Lazaros G; Gattorno M; LeWinter M; Abbate A; Brucato A; Klein A
Eur Heart J; 2022 Aug; 43(31):2946-2957. PubMed ID: 34528670
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis.
Abadie BQ; Cremer PC
BioDrugs; 2022 Jul; 36(4):459-472. PubMed ID: 35639340
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of anakinra for idiopathic and non-idiopathic pericarditis refractory or intolerant to conventional therapy.
Shaukat MH; Singh S; Davis K; Torosoff M; Peredo-Wende R
Eur Heart J Acute Cardiovasc Care; 2020 Dec; 9(8):888-892. PubMed ID: 32159368
[TBL] [Abstract][Full Text] [Related]
32. Rilonacept use in lupus pericarditis.
Fava A; Cammarata M; Adamo L
Clin Exp Rheumatol; 2024 May; 42(5):1115-1117. PubMed ID: 38526001
[TBL] [Abstract][Full Text] [Related]
33. Anakinra in idiopathic recurrent pericarditis refractory to immunosuppressive therapy; a preliminary experience in seven patients.
Dagan A; Langevitz P; Shoenfeld Y; Shovman O
Autoimmun Rev; 2019 Jun; 18(6):627-631. PubMed ID: 30959216
[TBL] [Abstract][Full Text] [Related]
34. Pharmacologic treatment of acute and recurrent pericarditis: a systematic review and meta-analysis of controlled clinical trials.
Avondo S; Andreis A; Casula M; Biondi-Zoccai G; Imazio M
Panminerva Med; 2021 Sep; 63(3):314-323. PubMed ID: 34738773
[TBL] [Abstract][Full Text] [Related]
35. A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis.
Scott IC; Hajela V; Hawkins PN; Lachmann HJ
J Cardiol Cases; 2011 Oct; 4(2):e93-e97. PubMed ID: 30534275
[TBL] [Abstract][Full Text] [Related]
36. Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of published evidence.
Lazaros G; Imazio M; Brucato A; Vassilopoulos D; Vasileiou P; Gattorno M; Tousoulis D; Martini A
J Cardiovasc Med (Hagerstown); 2016 Apr; 17(4):256-62. PubMed ID: 26090915
[TBL] [Abstract][Full Text] [Related]
37. Advances in pharmacotherapy for acute and recurrent pericarditis.
Vecchié A; Del Buono MG; Mauro AG; Cremer PC; Imazio M; Klein AL; Abbate A; Dentali F; Bonaventura A
Expert Opin Pharmacother; 2022 Apr; 23(6):681-691. PubMed ID: 35311434
[TBL] [Abstract][Full Text] [Related]
38. Emerging Therapies for Recurrent Pericarditis: Interleukin-1 inhibitors.
Lo Presti S; Elajami TK; Reyaldeen R; Anthony C; Imazio M; Klein AL
J Am Heart Assoc; 2021 Oct; 10(19):e021685. PubMed ID: 34569270
[TBL] [Abstract][Full Text] [Related]
39. Acute recurrent pericarditis: from pathophysiology towards new treatment strategy.
Cacoub P; Marques C
Heart; 2020 Jul; 106(14):1046-1051. PubMed ID: 32238419
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Adults with Idiopathic Recurrent Pericarditis: Novel Use of Immunotherapy.
Schwier NC; Hale GM; Davies ML
Pharmacotherapy; 2017 Mar; 37(3):305-318. PubMed ID: 28079270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
